AbbVie (NYSE: ABBV) reported third‑quarter 2026 worldwide revenue of USD 17.4 billion, up 10.3% year‑on‑year, driven by strong growth in immunology and neuroscience. The company raised its full‑year adjusted earnings per share (EPS) guidance to USD 13.95–13.99, compared with its previous forecast of USD 13.76–13.96.
Raised to USD 13.95–13.99 (prior: USD 13.76–13.96)
–
Franchise & Product Performance
Franchise / Product
Q3 2026 Revenue
YoY Change
Notes
Skyrizi (risankizumab)
USD 5.78 bn
+22.7%
Immunology growth leader
Rinvoq (upadacitinib)
USD 2.71 bn
+23.9%
JAK inhibitor franchise
Skyrizi + Rinvoq combined
USD 8.49 bn
–
Nearly half of AbbVie’s quarterly revenue
Humira (adalimumab)
USD 683 mn
−31.2%
Biosimilar competition
Vraylar (cariprazine)
USD 1.07 bn
+14.3%
Neuroscience
Botox Therapeutics
USD 1.08 bn
+9.8%
Neuroscience
Vyalev (foslevodopa/foscarbidopa)
USD 286 mn
Newer launch
Parkinson’s disease treatment
Ubrelvy + Qulipta (migraine)
USD 847 mn combined
–
Ubrogepant and atogepant
Venclexta (venetoclax)
USD 803 mn
+10.7%
Oncology
Elahere (mirvetuximab soravtansine)
USD 224 mn
+31%
Oncology
Imbruvica (ibrutinib)
Not disclosed
Declining
Partly offset oncology gains
Geographic Revenue – International Sales Rise 10% on Immunology Growth
Region
Q3 2026 Revenue
YoY Change
United States
USD 13.33 bn
+10.5% (≈77% of global sales)
International (total)
USD 4.07 bn
+9.8% (+10.6% at constant currency)
International – Immunology
USD 1.85 bn
+14.1%
International – Skyrizi
USD 757 mn
+21.6%
International – Rinvoq
USD 782 mn
+25.1%
International – Humira
USD 311 mn
−16.8%
International – Neuroscience
USD 450 mn
+20% (incl. USD 132 mn from Vyalev)
Nine‑Month International Momentum: International sales increased 14% to USD 12.23 billion in the first nine months of 2026.
Pipeline Expansion: AbbVie completed its acquisition of Apogee Therapeutics during Q3, expanding its immunology pipeline.
Market Impact & Outlook
Post‑Humira Transition Confirmed: With Skyrizi (+22.7%) and Rinvoq (+23.9%) together generating nearly half of quarterly revenue, AbbVie has effectively replaced the Humira earnings base – Humira’s 31.2% decline now represents a shrinking single‑digit share of total sales.
Guidance Raise Signals Confidence: Lifting adjusted EPS guidance to USD 13.95–13.99 reflects management’s conviction in continued immunology and neuroscience momentum through year‑end.
Neuroscience Scaling:19.4% growth to USD 3.39 billion, powered by Vraylar, Botox Therapeutics, the Vyalev Parkinson’s launch, and an USD 847 million migraine franchise, establishes neuroscience as the clear second growth engine.
International Re‑acceleration: Constant‑currency international growth of 10.6%, with immunology up 14.1% outside the U.S., demonstrates the global breadth of the Skyrizi/Rinvoq ramp.
Oncology Stabilization: Modest 0.8% growth – Venclexta (+10.7%) and Elahere (+31%) offsetting Imbruvica erosion – keeps the franchise steady while the Apogee acquisition deepens the immunology pipeline for the next cycle.
Forward‑Looking Statements This brief contains forward‑looking statements regarding AbbVie’s revenue guidance, adjusted EPS expectations, product launches, and commercialization performance. Actual results may differ materially due to risks including biosimilar competition, pricing and reimbursement pressures, foreign‑exchange fluctuations, regulatory outcomes, and commercialization execution. Figures are as reported in the company’s Q3 2026 results.-Fineline Info & Tech
Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.
